Journal
MOLECULAR ASPECTS OF MEDICINE
Volume 45, Issue -, Pages 14-27Publisher
ELSEVIER
DOI: 10.1016/j.mam.2015.06.002
Keywords
Biomarkers; Personalized medicine; Gastrointestinal malignancy; Gastric cancer; Pancreatic cancer; Colorectal cancer
Funding
- Roche/Genentech
- Lily/ Imclone
- BMS
- Synta Pharmaceuticals
- Pfizer
- Novartis
- Cleave Biotech
- Kirin Pharmaceuticals
- Boston Biomedical Incorp (BBI)
Ask authors/readers for more resources
Gastrointestinal malignancies are a major health care challenge due to the high incidence and overall poor outcome. A biomarker is a molecular characteristic of a tumor that may be utilized in the initial risk assessment and the subsequent management of the patient. This review focuses on the most pertinent prognostic and predictive biomarkers used in the clinical management of gastric, pancreas, and colon cancer. The available assays, limitations and clinical use for each biomarker are reviewed. The clinical trials evaluating novel biomarkers in GI cancers are discussed. (C) 2015 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available